This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
A new report from Dr. Michael Worobey alleges that it is likely that COVID-19 originated from a raccoon dog at the Wuhan live animal market in China. While his report does not rule out the coronavirus could have escaped from a lab, Worobey's evidence points to a natural origin.
Jill and Carlo are back to cover the latest in the Rittenhouse trial, new information on the origins of Covid, return-to-office and more.
JOIN US FOR THE YOUTUBE WATCH PARTY @ 9aET: http://www.youtube.com/cheddarnow
Over the weekend, Russia fired a missile at one of its own satellites, triggering an explosion that launched thousands of pieces of shrapnel through space and forced the astronauts aboard the International Space Station to shelter in place. Senior Writer from Space.com Chelsea 'Foxanne' Gohd, joined Cheddar to discuss more.
Gerald Comissiong, CEO of Todos Medical, joins None of the Above to discuss why we're seeing surges of COVID-19 cases in Europe, the potential for a winter surge of COVID-19, the benefits of high vaccination rates in a community, and the coming COVID treatment pills.
Cognitive healthcare platform BrainCheck recently raised $10 million in a Series B round. The platform offers neurologists a new way to detect and care for brain disorders like Alzeheimer's, and brain injuries like concussions. BrainCheck CEO Yael Katz joined Cheddar News' Closing Bell to discuss.
On this episode of Cheddar Innovates: Ice Barrel CEO breaks down the physical and mental health benefits to cold therapy training; Dishcraft CEO explains how its robotics is transforming the role of a dishwasher in restaurant kitchens; A look at Curiosity Stream's original series 'The Year That Rocked The World.'
Jill Wagner is joined by Baker to talk about kids and vaccines: we finally know how many young kids are getting vaccinated. Plus, Democrats are working on a Plan B for paid family leave. And the salad chain Sweetgreen goes public.
A breakthrough deal between the U.S. and China when it comes to climate has finally been reached. The two countries have pledged to work together to curb carbon emissions. Amy Harder, executive editor at Cipher, joined Cheddar News to discuss more.
Joey Roulette, space reporter for The New York Times, joined Cheddar to break down the intense backlash Russia is seeing after its missile test sent destroyed a non-functioning satellite and sent thousands of pieces of debris potentially at the ISS, endangering astronauts onboard. He said while the blast happened days ago, there is still some risk to the station as the space junk threat remains. So far, the U.S., NATO, and the European Union have condemned Russia for the test.
Jill is joined by “Friend of the Pod” Mosheh Oinounou to talk booster shots, and whether “fully vaccinated” will eventually mean three shots, not two. Plus, the latest on the Kyle Rittenhouse trial. And the research is in: we know now the perfect way to hug. Also, Jill and Mosheh debate whether Airpods are passé.
